You are here: Home: Audio Program Guide: BCU Surgeons 1 | 2007 Audio: BCU Surgeons 1 | 2007     Go to interview with J Michael Dixon, MD Go to interview with Maura N Dickler, MD Go to interview with William C Wood, MD Go to interview with John Mackey, MD   To listen to individual tracks, click the on the track you wish to listen to. To download tracks, right-click on the one you wish to download.       J Michael Dixon, MD Consultant Surgeon and Senior Lecturer Academic Office Edinburgh Breast Unit Western General Hospital Edinburgh, Scotland United Kingdom     Click here to download the entire interview   Track 1 Introduction Track 2 Variability in defining complete resection and adequate margins Track 3 Surgical approach to obtaining clear margins with acceptable cosmesis Track 4 Impact of wider margins on local recurrence rates Track 5 Incidence of local recurrence versus second primaries in patients undergoing breast-conserving therapy Track 6 Natural history of hormone receptor-positive breast cancer: Implications for longer-term management Track 7 Delayed adjuvant endocrine therapy Track 8 Surgeons’ management of adjuvant endocrine therapy Track 9 Monitoring and managing bone health in patients receiving adjuvant aromatase inhibitors Track 10 Vasomotor symptoms and arthralgias associated with aromatase inhibitors Track 11 Benefits of neoadjuvant therapy with aromatase inhibitors Track 12 Increasing the accuracy and efficiency of sentinel lymph node biopsy Track 13 Improving cosmesis of minimally invasive breast cancer surgical approaches       Maura N Dickler, MD Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering Cancer Center New York, New York     Click here to download the entire interview   Track 1 Introduction Track 2 Counseling patients about the risks and benefits of tamoxifen for DCIS Track 3 Use of aromatase inhibitors in postmenopausal patients with DCIS Track 4 STAR prevention trial: Tamoxifen versus raloxifene in postmenopausal women Track 5 Use of up-front adjuvant aromatase inhibitors versus sequencing after tamoxifen Track 6 Monitoring and managing bone health in women receiving adjuvant aromatase inhibitors Track 7 Long-term recurrence and management of hormone receptor-positive disease Track 8 Treatment with delayed adjuvant endocrine therapy Track 9 Treatment of premenopausal patients with hormone receptor-positive disease Track 10 Development of the Oncotype DX™ assay Track 11 TAILORx study: Prospective validation of the Oncotype DX assay Track 12 Clinical decision-making with the Oncotype DX assay Track 13 Overview of the adjuvant trastuzumab clinical trial data Track 14 Updated results of BCIRG 006 adjuvant trastuzumab trial Track 15 Treatment of patients with smaller node-negative, HER2-positive tumors Track 16 Dose-dense adjuvant AC followed by paclitaxel and trastuzumab Track 17 Variability in quality control for the assessment of HER2 status Track 18 Evaluation of anti-VEGF bevacizumab in adjuvant clinical trials       William C Wood, MD Joseph Brown Whitehead Professor and Chairman Department of Surgery Emory University School of Medicine Atlanta, Georgia     Click here to download the entire interview   Track 1 Introduction Track 2 Questions commonly asked by surgical oncologists about the treatment of breast cancer Track 3 Skin-sparing mastectomy Track 4 Incorporating the Oncotype DX assay in clinical practice Track 5 Utilizing the Oncotype DX assay to select which patients to treat with adjuvant chemotherapy Track 6 Chemotherapy with trastuzumab for patients with node-negative, HER2-positive disease Track 7 Benefit of adjuvant chemotherapy in patients with hormone receptor-positive disease Track 8 Assessment of HER2 and hormone receptor status with the Oncotype DX assay Track 9 Duration of use and long-term side effects of aromatase inhibitors Track 10 Long-term risk of relapse for patients with hormone receptor-positive tumors Track 11 Declines in breast cancer incidence in the United States Track 12 Advantages of neoadjuvant chemotherapy Track 13 Use of nanoparticles for tumor imaging Track 14 Use of neoadjuvant chemotherapy versus endocrine therapy Track 15 A physician’s perspective on undergoing surgery       John Mackey, MD Medical Oncologist, Cross Cancer Institute Professor, Medical and Experimental Oncology, University of Alberta Chair of Research, Northern Alberta Breast Cancer Program Director, Cancer International Research Group Edmonton, Canada     Click here to download the entire interview   Track 1 Introduction Track 2 Improved efficacy and survival with adjuvant aromatase inhibitors compared to tamoxifen Track 3 Monitoring and managing bone health in women receiving aromatase inhibitors Track 4 Time course of recurrence and duration of aromatase inhibitor therapy in postmenopausal patients with hormone receptor-positive disease Track 5 Use of delayed adjuvant endocrine therapy Track 6 Arthralgias associated with adjuvant aromatase inhibitor therapy Track 7 Vasomotor and gynecologic side effects of aromatase inhibitors compared to tamoxifen Track 8 Surgeons’ management of adjuvant aromatase inhibitor therapy Track 9 Bone density monitoring of patients receiving adjuvant aromatase inhibitors Track 10 Quality control for assessment of HER2 and hormone receptor status Track 11 Endocrine therapy for premenopausal patients Track 12 Benefits of adjuvant chemotherapy for patients with hormone receptor-positive disease Track 13 Use of the Oncotype DX assay in clinical decision-making Track 14 Potential role of the Oncotype DX assay in the assessment of ER and HER2   Search Our Site

Terms and Conditions of Use and General Disclaimer | Privacy Policy Copyright © 2007 Research To Practice, All Rights Reserved